Cibus, Inc.
NCM: CBUSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Cibus, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CBUS Z-Score →About Cibus, Inc.
Healthcare
Biotechnology
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
📊 Fundamental Analysis
Cibus, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -12.8% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -221.0%, which indicates that capital utilization is currently under pressure.
At a current price of $1.51, CBUS currently trades near the bottom of its 52-week range (14%), indicating potential value or weakness (Range: $1.09 - $4.19).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$122.03M
Trailing P/E
--
Forward P/E
-7.55
Beta (5Y)
1.93
52W High
$4.19
52W Low
$1.09
Avg Volume
613K
Day High
Day Low